Alnylam Pharmaceuticals Inc (ALNY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alnylam Pharmaceuticals Inc stock (ALNY) is currently trading at $328.70. Alnylam Pharmaceuticals Inc PE ratio is 131.65. Alnylam Pharmaceuticals Inc PS ratio (Price-to-Sales) is 11.00. Analyst consensus price target for ALNY is $449.32. WallStSmart rates ALNY as Underperform.
- ALNY PE ratio analysis and historical PE chart
- ALNY PS ratio (Price-to-Sales) history and trend
- ALNY intrinsic value — DCF, Graham Number, EPV models
- ALNY stock price prediction 2025 2026 2027 2028 2029 2030
- ALNY fair value vs current price
- ALNY insider transactions and insider buying
- Is ALNY undervalued or overvalued?
- Alnylam Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ALNY Piotroski F-Score and Altman Z-Score
- ALNY analyst price target and Smart Rating
Alnylam Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
ALNY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Alnylam Pharmaceuticals Inc (ALNY)
ALNY trades 1926% above its Graham fair value of $15.91, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Alnylam Pharmaceuticals Inc (ALNY) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, return on equity, revenue growth. Concerns around peg ratio and price/sales. Mixed signals suggest waiting for clearer direction before acting.
Alnylam Pharmaceuticals Inc (ALNY) Key Strengths (4)
Every $100 of shareholder equity generates $73 in profit
Revenue surging 84.90% year-over-year
101.85% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Alnylam Pharmaceuticals Inc (ALNY) Areas to Watch (5)
PEG ratio is negative or unavailable
Very expensive at 11.0x annual revenue
Very expensive at 52.5x book value
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Supporting Valuation Data
Alnylam Pharmaceuticals Inc (ALNY) Detailed Analysis Report
Overall Assessment
This company scores 47/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 4 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Revenue Growth, Institutional Own.. Profitability is solid with Return on Equity at 73.30%. Growth metrics are encouraging with Revenue Growth at 84.90%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (N/A), Price/Sales (11.00), Price/Book (52.46) suggest expensive pricing. Profitability pressure is visible in Operating Margin at 12.00%, Profit Margin at 8.45%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 73.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 84.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALNY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALNY's Price-to-Sales ratio of 11.00x trades at a deep discount to its historical average of 96.44x (1th percentile). The current valuation is 97% below its historical high of 356.66x set in Nov 2014, and 11% above its historical low of 9.92x in Aug 2011.
WallStSmart Analysis Synopsis
Data-driven financial summary for Alnylam Pharmaceuticals Inc (ALNY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Alnylam Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 3.7B with 85% growth year-over-year. Profit margins are thin at 8.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 85% YoY, reaching 3.7B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 73.3% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can Alnylam Pharmaceuticals Inc push profit margins above 15% as the business scales?
Growth sustainability: can Alnylam Pharmaceuticals Inc maintain 85%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 131.7x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Alnylam Pharmaceuticals Inc.
Bottom Line
Alnylam Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 85% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 8.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(261 last 3 months)
| Insider | Type | Shares |
|---|---|---|
FITZGERALD, KEVIN JOSEPH CSO & EVP, Head of Research | Buy | +158 |
| Insider | Type | Shares |
|---|---|---|
FITZGERALD, KEVIN JOSEPH CSO & EVP, Head of Research | Sell | -2,041 |
| Insider | Type | Shares |
|---|---|---|
ARBUCKLE, STUART A Director | Buy | +3,279 |
Data sourced from SEC Form 4 filings
Last updated: 2:52:25 PM
About Alnylam Pharmaceuticals Inc(ALNY)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.